UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On Wednesday, May 29, 2024, 89bio, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) at 9:00 a.m. Pacific Time. As of the close of business on April 4, 2024, the record date for the Annual Meeting, there were 95,224,724 shares of common stock entitled to vote at the meeting.
At the Annual Meeting, each of the Company’s director nominees was elected, a frequency of one year received the plurality of votes on Proposal 4, and each of the other proposals voted on were approved. The final voting results are set forth below:
| Votes For |
Votes Withheld |
Broker Non-Votes | ||||||||||||
| Proposal 1. Election of Class II Directors |
||||||||||||||
| • Steven M. Altschuler, M.D. |
78,767,873 | 870,306 | 5,519,919 | |||||||||||
| • Michael Hayden, M.B. Ch.B., Ph.D. |
74,810,576 | 4,827,603 | 5,519,919 | |||||||||||
| • Kathleen LaPorte |
41,297,162 | 38,341,017 | 5,519,919 | |||||||||||
| Votes For |
Votes Against |
Abstentions | Broker Non-Votes | |||||||
| Proposal 2. Ratification of KPMG LLP as Independent Auditor |
85,047,829 | 21,903 | 88,366 | 0 | ||||||
| Votes For |
Votes Against |
Abstentions | Broker Non-Votes | |||||||
| Proposal 3. Advisory Vote on Executive Compensation |
78,521,244 | 1,100,672 | 16,263 | 5,519,919 | ||||||
| 1 Year | 2 Years | 3 Years | Abstentions | Broker Non-Votes |
||||||||
| Proposal 4. Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation |
68,467,710 | 4,205 | 17,657 | 11,148,607 | 5,519,919 | |||||||
In light of these voting results, the Company plans to hold future advisory votes on executive compensation annually until the next required vote on the frequency of such advisory votes, or until the Board of Directors of the Company otherwise determines that a different frequency is in the best interests of the Company and its stockholders.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| 89bio, Inc. | ||||||
| Date: May 31, 2024 | By: | /s/ Rohan Palekar | ||||
| Rohan Palekar | ||||||
| Chief Executive Officer | ||||||
Document and Entity Information |
May 29, 2024 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | false |
| Entity Central Index Key | 0001785173 |
| Document Type | 8-K |
| Document Period End Date | May 29, 2024 |
| Entity Registrant Name | 89bio, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-39122 |
| Entity Tax Identification Number | 36-4946844 |
| Entity Address, Address Line One | 142 Sansome Street |
| Entity Address, Address Line Two | Second Floor |
| Entity Address, City or Town | San Francisco |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94104 |
| City Area Code | (415) |
| Local Phone Number | 432-9270 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | ETNB |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |